How TechBio is speeding up clinical trials and cutting through red tape

In this longform interview, Sana Capital Managing Partner Hanadi Jabado explains how TechBio radically accelerates clinical trials, collapses regulatory bottlenecks, and drives faster, cheaper, more patient-centred medical innovation.

From AI-assisted imaging (Qureight) to at-home diagnostics (ExSeed) and virtual wards (Feebris), she shows how technology and data can reshape trial recruitment, automate analysis, broaden participant diversity, and give regulators real-time evidence — ultimately shifting healthcare from hospital-centric to distributed, data-led, prevention-first models.

Hanadi also outlines what differentiated TechBio investors must bring: native fluency in both life sciences and tech, business-model innovation, and a patient-centric mission — not just capital.

Click below to read the full interview on Campden FB's website:

Campden FB: How TechBio is speeding up clinical trials and cutting through red tape